ALT 801

Drug Profile

ALT 801

Alternative Names: 264scTCR/IL-2; ALT-801; STAR™-Ck

Latest Information Update: 07 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altor BioScience Corporation
  • Developer Altor BioScience Corporation; Florida Department of Health; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer; Multiple myeloma; Urogenital cancer
  • Phase I Acute myeloid leukaemia
  • No development reported Malignant melanoma

Most Recent Events

  • 04 Oct 2016 Altor Bioscience and NantKwest agree to co-develop combination immunotherapies for Cancer
  • 13 Jul 2016 Altor Bioscience terminates its phase Ib/II trial for Multiple myeloma (Second-line therapy or greater) in USA as patients did not benefit from single agent treatment(NCT01670994)
  • 11 Apr 2016 Altor BioScience establishes CRADA with National Cancer Institute for the development of ALT 801 and ALT 803
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top